Latest News and Press Releases

LAWRENCE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is pleased to announce the acceptance of the Phase I proof of concept study of the pharmacology of BTI-320 prior to...

LAWRENCE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel...

LAWRENCE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel...

LAWRENCE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE) is pleased to announce that it has entered into a non-binding letter of intent...

LAWRENCE, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (the “Company” or “BTI”) (OTCQB:BTHE) is pleased to announce that it has won a patent position argued with the European Patent...

LAWRENCE, Mass., March 29, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, an innovator in the design, development and commercialization of novel treatments for diabetes and its related complications,...

LAWRENCE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, an innovator in the design, development and early commercialization of novel therapeutics for the potential treatment of...

LAWRENCE, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc announces their new participation in MassBIO, an unparalleled network of innovative companies and industry thought...

LAWRENCE, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. announces that Loraine V. Upham will join the team to lead the US operations and drug development effort for the diabetes...

LAWRENCE, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (Boston Therapeutics) announces the acquisition of CureDM Group Holdings, LLC (CureDM), adding a Phase 2-ready drug to...